Atenolol/Hydrochlorothiazide/Ramipril/Simvastatin

阿替洛尔/氢氯噻嗪/雷米普利/辛伐他汀

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAtenolol/Hydrochlorothiazide/Ramipril/Simvastatin
Drug Alias Name氢氯噻嗪-辛伐他汀-雷米普利-阿替洛尔Hydrochlorothiazide+Simvastatin+Ramipril+AtenololSimvastatin/Atenolol/Hydrochlorothiazide/Ramipril氢氯噻嗪+辛伐他汀+雷米普利+阿替洛尔Hydrochlorothiazide/Simvastatin/Ramipril/Atenolol +[10] 
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsThiazide-sensitive sodium-chloride cotransporter inhibitorsAngiotensin-converting enzyme inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterVoltage-gated calcium channelAdrenergic receptors +[5] 
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsCardiovascular Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2014/01/01
Country/TerritoryIndia
CombinationsYes HydrochlorothiazideAtenololRamipril
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCadila Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZydus Lifesciences Ltd
Inactive CompaniesN/A
Active IndicationsCardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeC10BA
Related LinksN/A